Published in Oncoscience on April 30, 2014
The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol (2016) 0.79
FABP-1 gene ablation impacts brain endocannabinoid system in male mice. J Neurochem (2016) 0.77
The potential relevance of the endocannabinoid, 2-arachidonoylglycerol, in diffuse large B-cell lymphoma. Oncoscience (2016) 0.75
Endocannabinoids as Guardians of Metastasis. Int J Mol Sci (2016) 0.75
Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents. Front Pharmacol (2016) 0.75
Anti-proliferative, pro-apoptotic and anti-invasive effect of EC/EV system in human osteosarcoma. Oncotarget (2017) 0.75
Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 13.60
Inflammation and cancer: how hot is the link? Biochem Pharmacol (2006) 5.17
Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science (2011) 3.48
Cancer immunoediting from immune surveillance to immune escape. Immunology (2007) 3.03
Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest (1997) 2.99
Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes (2006) 2.40
Wound-healing assay. Methods Mol Biol (2005) 2.28
Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol (2007) 2.08
Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem (2009) 1.91
Possible endocannabinoid control of colorectal cancer growth. Gastroenterology (2003) 1.89
Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem Rev (2011) 1.56
Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol (2003) 1.47
The endocannabinoid system and cancer: therapeutic implication. Br J Pharmacol (2011) 1.46
Opioids as modulators of cell death and survival--unraveling mechanisms and revealing new indications. Pharmacol Rev (2004) 1.40
Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res (2006) 1.40
E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res (2000) 1.31
Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J Natl Cancer Inst (2007) 1.23
Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J (2001) 1.14
Analysis of endocannabinoids by Ag+ coordination tandem mass spectrometry. Anal Biochem (2003) 1.13
Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol Immunother (2004) 1.12
Cannabinoids in pancreatic cancer: correlation with survival and pain. Int J Cancer (2008) 1.09
Expression and function of fatty acid amide hydrolase in prostate cancer. Int J Cancer (2008) 1.09
Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4. PLoS One (2010) 1.08
R-flurbiprofen reduces neuropathic pain in rodents by restoring endogenous cannabinoids. PLoS One (2010) 1.08
Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: Location, hydrolysis and 12-lipoxygenase metabolism. Int J Cancer (2007) 1.07
Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer (2010) 1.07
Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. Cancer Prev Res (Phila) (2010) 1.03
Krill oil significantly decreases 2-arachidonoylglycerol plasma levels in obese subjects. Nutr Metab (Lond) (2011) 1.02
Anandamide enhances IL-10 production in activated microglia by targeting CB(2) receptors: roles of ERK1/2, JNK, and NF-kappaB. Glia (2010) 0.99
G protein-coupled receptor-mediated mitogen-activated protein kinase activation through cooperation of Galpha(q) and Galpha(i) signals. Mol Cell Biol (2000) 0.97
Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion. PLoS One (2011) 0.97
Cyclooxygenase-2 mediates anandamide metabolism in the mouse brain. J Pharmacol Exp Ther (2010) 0.96
Estimation of reference intervals of five endocannabinoids and endocannabinoid related compounds in human plasma by two dimensional-LC/MS/MS. J Lipid Res (2011) 0.94
The endocannabinoid system in prostate cancer. Nat Rev Urol (2011) 0.92
Anandamide inhibits macrophage-mediated killing of tumor necrosis factor-sensitive cells. Life Sci (1995) 0.92
2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL-60 cells. J Biochem (2004) 0.91
Anandamide and Delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors. J Neuroimmunol (2007) 0.89
Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (review). Oncol Rep (2007) 0.89
The association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma growth through a supra-additive action. BMC Cancer (2012) 0.89
The putative cannabinoid receptor GPR55 promotes cancer cell proliferation. Oncogene (2010) 0.88
The PPARγ agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft model. Cancer Chemother Pharmacol (2013) 0.84
Peroxisome proliferator-activated receptor-γ activation inhibits hepatocellular carcinoma cell invasion by upregulating plasminogen activator inhibitor-1. Cancer Sci (2013) 0.84
The endocannabinoid system in the cancer therapy: an overview. Curr Med Chem (2011) 0.81
Management of Microbiological Samples in a Confirmed Case of Ebola Virus Disease: Constraints and Limitations. J Clin Microbiol (2015) 0.77